German Sativex pricing saga could end free pricing holiday
This article was originally published in Scrip
Executive Summary
Companies could see lower prices take effect sooner and potential delays to launch if German policy makers do way with the 12 month grace period of free pricing for new drugs before the outcome of the AMNOG benefit assessments and pricing talks kick in, warned Wolfgang Kaesbach, former head of the pharmaceutical department of the GKV, the national association of statutory health insurers.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.